Radnostix INIS

Radnostix Inc. manufactures a wide range of radioisotope-focused products used in medical and industrial applications. The company produces and distributes isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications. Its core business consists of five reportable segments including Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The company operates through specialized facilities and subsidiaries to support production, distribution, and regulatory compliance for its products across domestic and international markets.

Radnostix Inc. generates revenue through the production, distribution, and sale of its radioisotope-based products and related services. Revenue streams include the sale of generic sodium iodide I-131 drug products, cobalt-60 sealed sources, calibration and reference standards for nuclear medicine equipment, medical devices such as the EasyFill Automated Capsule System and RadVent products, and fluorine gases produced via its Fluorine Extraction Process. The company serves customers in the radiopharmacy, clinical research, industrial operations, and nuclear medicine sectors, with products shipped directly to all 50 U. S. states and select international locations. Revenue is derived from both proprietary product lines and third-party distribution agreements, including those with Scintomics ATT and PhanTech.

The company operates through the following segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.

• Theranostics Products: This segment includes the production and distribution of isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications. The company produces its FDA-approved generic sodium iodide I-131 drug product, which is the only generic version of this type manufactured in the U. S. Additionally, this segment distributes APIs and radiochemicals from third-party suppliers for preclinical, industrial, and research use, supporting drug development and clinical trial applications.
• Cobalt Products: This segment involves the production of cobalt-60 sealed sources for radiation therapy, industrial applications, and recycling of expended sources. The company fabricates cobalt-60 products used in gamma sterilization, security devices, radiography, and cancer treatment, leveraging its experienced staff to comply with NRC, DOT, and international regulatory requirements. It emphasizes its domestically manufactured offerings as providing a competitive edge over foreign suppliers in the North American market.
• Calibration & Reference Products: This segment consists of sealed source calibration and reference products, including internally manufactured, jointly manufactured, and third-party items. Products include flood sources, dose calibrator sources, phantoms, rod and line sources, rulers, markers, and specialty design items used with SPECT and PET imaging equipment, lab systems, and CDMO facilities. The segment also commercializes bulk isotope sales, shielding, and accessories, with products distributed through the RadQual subsidiary and used for routine equipment calibration and operational testing.
• Medical Devices: This segment includes the development and distribution of medical devices, both proprietary and third-party. Key products under development include the EasyFill Automated Capsule System for I-131 encapsulation and the RadVent line of lung imaging systems acquired from AMICI, Inc. The segment also distributes and services Scintomics ATT’s radiosynthesis modules under an exclusive U. S. and Canada agreement, with all current Medical Devices segment revenue derived from third-party product sales.
• Fluorine Products: This segment supports the production and sale of fluoride gases using the Fluorine Extraction Process (FEP), originally intended to support a depleted uranium de-conversion facility in Lea County, New Mexico. Although the de-conversion facility development was suspended in 2013 due to reduced demand, the company maintains all related NRC licenses and permits. In March 2026, it terminated an asset purchase agreement with American Fuel Resources to regain control of the Fluorine Products segment and associated assets, with plans to evaluate options for developing the DUF6 Plant into an operating entity focused on uranium deconversion.

Radnostix Inc. operates in a specialized industry with high barriers to entry due to regulatory, technical, and expertise requirements. The company competes with Jubilant DraxImage and Eckert & Ziegler in theranostics and calibration products, Nordion in cobalt-60 sources, and Epsilon Radioactive Sources in select markets. Its competitive advantages include domestic production of FDA-approved sodium iodide I-131, NRC licensing for high-activity isotopes, cGMP compliance, and experienced technical staff. The company also benefits from ISO certifications and strategic OEM alignments that enhance its market position in medical and industrial isotope applications.

Radnostix Inc. serves customers including radiopharmacies, clinical research organizations, hospitals, nuclear medicine clinics, industrial operators, utilities, mining operations, and government laboratories. Specific customer channels involve distributors who make direct sales to end-users in the U. S. and internationally. The company’s products are used in PET and SPECT imaging, radiation therapy, lab equipment calibration, and pharmaceutical development, with recurring demand due to the periodic replacement of calibration sources with useful lives averaging eighteen months to two years.